Tran Dien Minh, Vu Uyen Tu Thi, Hoang Canh Ngoc, Nguyen Ha Thu Thi, Nguyen Phu Huy, Tran Mai Chi Thi, Chu Anh Ngoc, Phan Phuc Huu
Surgical Intensive Care Unit, Vietnam National Children's Hospital, 18/879 Lathanh Street, Hanoi 100000, Vietnam.
Department of Biochemistry, Vietnam National Children's Hospital, 18/879 Lathanh Street, Hanoi 100000, Vietnam.
Pathogens. 2022 Nov 30;11(12):1442. doi: 10.3390/pathogens11121442.
Background: The robustness of sero-surveillance has delineated the high burden of SARS-CoV-2 infection in children; however, these existing data showed wide variation. This study aimed to identify the serostatus of antibodies against SARS-CoV-2 and associated factors among children following the fourth pandemic wave in Vietnam. Methods: A cross-sectional study was conducted at Vietnam National Children’s Hospital (VNCH) between March 13 and April 3, 2022. Thus, 4032 eligible children seeking medical care for any medical condition not related to acute COVID-19 infection were tested for IgG SARS-CoV-2 antibodies by ADVIA Centaur® SARS-CoV-2 IgG (sCOVG) assay using the residuals of routine blood samples. Results: The median age of enrolled children was 39 (IQR = 14−82) months. The overall seropositive prevalence was 59.2% (95%CI = 57.6−60.7) and the median antibody titer was 4.78 (IQR 2.38−9.57) UI/mL. The risk of seropositivity and the median antibody titer were not related to gender (58.6% versus 60.1%, 4.9 versus 4.6 UI/mL, all p > 0.05). Children aged ≤12 months were likely to be seropositive compared to children aged 36 to <60 months (59.2% versus 57.5%, p = 0.49) and those aged ≥144 months (59.2% versus 65.5%, p = 0.16). Children aged ≥144 months exhibited a significantly higher titer of protective COVID-19 antibodies than other age groups (p < 0.001). In multivariate logistic regression, we observed independent factors associated with SARS-CoV-2 seropositivity, including the age 13 to <36 months (OR = 1.29, 95%CI = 1.06−1.56, p = 0.01), 60 to <144 months (OR = 0.79, 95%CI = 0.67−0.95, p = 0.01), ≥144 months (OR = 1.84, 95%CI = 1.21−2.8, p = 0.005), the presence of infected household members (OR = 2.36, 95%CI = 2.06−2.70, p < 0.001), participants from Hanoi (OR = 1.54, 95%CI = 1.34−1.77, p < 0.001), underlying conditions (OR = 0.71, 95%CI = 0.60−0.85, p ≤ 0.001), and using corticosteroids or immunosuppressants (OR = 0.64, 95%CI = 0.48−0.86, p = 0.003). Conclusions: This study highlights a high seroprevalence of antibodies against SARS-CoV-2 among children seeking medical care for non-acute COVID-19-related conditions in a tertiary children’s hospital in Hanoi, Vietnam. In the context of reopening in-person schools and future emerging COVID-19 variants, this point will also be a key message about the necessity of “rush-out” immunization coverage for children, especially those under the age of five years.
血清学监测的稳健性已明确了儿童中SARS-CoV-2感染的高负担;然而,这些现有数据显示出很大差异。本研究旨在确定越南第四波疫情高峰后儿童中抗SARS-CoV-2抗体的血清学状态及相关因素。方法:于2022年3月13日至4月3日在越南国家儿童医院(VNCH)开展了一项横断面研究。因此,对4032名因与急性COVID-19感染无关的任何病症寻求医疗护理的符合条件儿童,使用常规血液样本的剩余部分,通过ADVIA Centaur® SARS-CoV-2 IgG(sCOVG)检测法检测SARS-CoV-2 IgG抗体。结果:纳入儿童的中位年龄为39(四分位间距=14−82)个月。总体血清阳性率为59.2%(95%置信区间=57.6−60.7),中位抗体滴度为4.78(四分位间距2.38−9.57)UI/mL。血清阳性风险和中位抗体滴度与性别无关(58.6%对60.1%,4.9对4.6 UI/mL,所有p>0.05)。与36至<60个月龄儿童(59.2%对57.5%,p=0.49)和≥144个月龄儿童(59.2%对65.5%,p=0.16)相比,≤12个月龄儿童血清阳性的可能性更大。≥144个月龄儿童的保护性COVID-19抗体滴度显著高于其他年龄组(p<0.001)。在多因素逻辑回归中,我们观察到与SARS-CoV-2血清阳性相关的独立因素,包括13至<36个月龄(比值比=1.29,95%置信区间=1.06−1.56,p=0.01)、60至<144个月龄(比值比=0.79,95%置信区间=0.67−0.95,p=0.01)、≥144个月龄(比值比=1.84,95%置信区间=1.21−2.8,p=0.005)、有感染的家庭成员(比值比=2.36,95%置信区间=2.06−2.70,p<0.001)、来自河内的参与者(比值比=1.54,95%置信区间=1.34−1.77,p<0.001)、基础疾病(比值比=0.71,95%置信区间=0.60−0.85,p≤0.001)以及使用皮质类固醇或免疫抑制剂(比值比=0.64,95%置信区间=0.48−0.86,p=0.003)。结论:本研究强调了在越南河内一家三级儿童医院中,因非急性COVID-19相关病症寻求医疗护理的儿童中抗SARS-CoV-2抗体的高血清阳性率。在重新开放面对面授课学校以及未来出现COVID-19新变种的背景下,这一点也将是关于儿童尤其是五岁以下儿童“紧急”免疫接种覆盖率必要性的关键信息。